What Is the Antidiarrheal Lopermid (Loperamide Hydrochloride)? How Is It Used?
Reading tools
In this article
What Is Loperamide and What Is It Used For?
Loperamideis a medicine that controls diarrhea by slowing bowel movements. Its only authorized brand in Turkey is Lopermid 2 mg tablets(Saba İlaç). Imodium, the best-known brand worldwide, is not marketed in Turkey; no other product containing loperamide is available in the country.
In oncology practice, loperamide has a role far beyond a simple antidiarrheal. Diarrhea caused by chemotherapy and targeted drugs can lead to treatment interruptions, dose reductions, hospitalization and, rarely, death. When loperamide controls it early, it helps ensure uninterrupted treatment .
Summary of This Article
- Loperamide is not an over-the-counter medicine in Turkey. It requires a standard white prescription and is reimbursed by SGK. Its OTC status in the US and many European countries does not apply in Turkey.
- The maximum daily dose in Turkey is 12 mg (6 tablets), and the drug is contraindicated below age 12. The US label differs, with a 16 mg maximum and an under-2 age limit; the Summary of Product Characteristics applicable in Turkey governs local use.
- In the US, prescription loperamide products carry a boxed warning : high doses can cause torsades de pointes, cardiac arrest and sudden death.
- For irinotecan-associated delayed diarrhea, the intensive regimen intentionally exceeds the maximum daily dose. This is a regimen that patients must not use on their own at home.
- Loperamide alone is dangerous in immunotherapy-related colitis: it masks symptoms, delays initiation of corticosteroids and increases the risk of toxic megacolon.
- The older text we replaced contained an incorrect homemade oral rehydration recipe , with twice the required amount of salt. The correct recipe is provided in this article.
- Current price: 69.84 TL (20 tablets, August 31, 2026 price list).
How Does It Work?
Loperamide acts on the nerve network (myenteric plexus) in the intestinal wall by stimulating mu-opioid receptors . Structurally, it belongs to the morphine family; however, at normal doses it does not produce the pain-relieving or addictive effects expected of an opioid. There are two reasons for this:
- Very little reaches the bloodstream after oral administration. Bioavailability is below 1%; the drug acts within the intestine.
- It cannot enter the brain. At the blood-brain barrier, the P-glycoprotein pump sends loperamide back where it came from. The underlying mechanism of abuse and cardiac poisoning is the pump's saturation at very high doses.
| Step | What Happens | Result |
|---|---|---|
| 1 | Mu-opioid receptors in the intestinal wall are stimulated | Acetylcholine and prostaglandin release from nerve endings decreases |
| 2 | Peristaltic movements slow | Transit time of intestinal contents increases |
| 3 | The colon remains in contact with the contents longer | Water and electrolyte reabsorption increases |
| 4 | Anal sphincter tone increases | Urgency and the feeling of leakage decrease |
| 5 | Stool consistency improves | Bowel movements become less frequent and dehydration risk decreases |
A Critical Distinction: Loperamide does not treat the cause of diarrhea; instead, it slows its consequences . This distinction underlies every warning in the rest of this article: if a microorganism or toxin needs to be expelled, keeping it in the intestine makes the situation worse, not better.
Status in Turkey: Price, Prescription and Reimbursement
| Item | Information |
|---|---|
| Product | Lopermid 2 mg tablets, 20 tablets per pack |
| Barcode | 8699511010077 |
| Retail price | 69.84 TL (including VAT) |
| Price list date | August 31, 2026. The price has not changed since March 31, 2026 (previously: 64.47 TL / 16.03.2026, and 60.77 TL / until 02.03.2026). |
| Marketing authorization holder | Saba İlaç San. ve Tic. A.Ş. (İstanbul) |
| Manufacturing site | Deva Holding A.Ş. (Çerkezköy) |
| Authorization number / date | 195/16 — 07.04.2000 |
| ATC code | A07DA03 |
| Prescription status | White (standard) prescription |
| SGK | Reimbursed (reimbursement code A04735) |
| Other brands | None. Imodium is not authorized in Turkey; no equivalent product is available. |
A Common Misconception: “Loperamide Is an Over-the-Counter Medicine.”
This statement is true for the US, the UK and many EU countries; it is not true for Turkey. In Turkey, human medicinal products are classified as prescription or nonprescription under the regulation dated February 17, 2005, and Lopermid is in the prescription category. The fact that pharmacies may dispense it without a prescription in practice does not change its legal status and, more importantly, does not mean the drug is safe without limits. The list of situations in which loperamide should not be used is long, and patients cannot distinguish most of them themselves.
This statement is true for the US, the UK and many EU countries; it is not true for Turkey. In Turkey, human medicinal products are classified as prescription or nonprescription under the regulation dated February 17, 2005, and Lopermid is in the prescription category. The fact that pharmacies may dispense it without a prescription in practice does not change its legal status and, more importantly, does not mean the drug is safe without limits. The list of situations in which loperamide should not be used is long, and patients cannot distinguish most of them themselves.
Differences Between the Turkish and US Labels — this is among the most practical information in this article. Most English-language sources found online describe the US label, and the limits applicable in Turkey are narrower:
Note: Older package leaflets may state “8 tablets (16 mg)” and “not recommended below age 9.” The applicable reference is the updated Summary of Product Characteristics dated March 26, 2025: 12 mg and age 12.
| Turkey (Lopermid SmPC, 26.03.2025) | US | |
|---|---|---|
| Maximum daily dose | 12 mg (6 tablets) | 8 mg (nonprescription) / 16 mg (prescription) |
| Age limit | Contraindicated below age 12 | Contraindicated below age 2 |
| Indication | Acute diarrhea in adults and children aged ≥12; acute diarrhea due to IBS in adults after physician diagnosis | Acute diarrhea, travelers' diarrhea, chronic diarrhea (prescription) |
Dosing Regimens
1. Acute Diarrhea (Without Fever or Blood)
| Step | Turkey (SmPC) | Explanation |
|---|---|---|
| Initial dose | 4 mg (2 tablets) | After the first loose stool |
| Continuation | After each loose bowel movement 2 mg (1 tablet) | Stop when stools become formed |
| Daily maximum | 12 mg (6 tablets) | Must not be exceeded |
| Duration | Usually 48 hours | Seek medical advice if there is no improvement within 48 hours |
| Below age 12 | Do not use | Contraindicated in Turkey |
The “One Tablet Will Do” Mistake. The most common misuse of loperamide is to take a single tablet and wait. Correct use consists of a loading dose (4 mg) + maintenance after each diarrheal stool (2 mg) , without exceeding the daily maximum. Conversely, continuing “just to be sure” after stools begin to form also causes constipation and, rarely, paralytic ileus .
2. Chemotherapy-Associated Diarrhea — Irinotecan Delayed Diarrhea
Two types of diarrhea occur during irinotecan treatment. Early diarrhea (within the first 24 hours) is cholinergic and is treated with atropine ; loperamide has no role. Delayed diarrhea (after 24 hours, typically on days 5-11) is caused by intestinal mucosal damage, and loperamide is central to its treatment.
The regimen described in the irinotecan (Camptosar) prescribing information is:
| Timing | Dose |
|---|---|
| At the first loose stool | 4 mg loading dose |
| Daytime | 2 mg every 2 hours |
| At night (to avoid interrupting sleep) | 4 mg every 4 hours |
| Until when? | Until the patient has been free of diarrhea for at least 12 hours continuously |
| Maximum duration | 48 consecutive hours — because of the risk of paralytic ileus |
This regimen intentionally exceeds the maximum daily dose. The arithmetic is clear: a 4 mg loading dose + 2 mg every 2 hours over 24 hours = 28 mg per day. This is far above the 12 mg limit in Turkey and the 16 mg US limit. It is not a mistake, but a deliberate exception that applies only under the following three conditions:
- The prescribing oncologist must have explicitly specified this regimen ,
- The duration must not exceed 48 hours,
- If fever, bloody stools or neutropenia are present, do not use it — these require hospital assessment.
3. Neratinib Prophylaxis: A Changing Practice
Used in HER2-positive breast cancer, neratinib (Nerlynx) is among the most challenging drugs for diarrhea. In ExteNET, patients receiving no prophylaxis had Grade 3 diarrhea in 40% of cases , and 17% stopped the drug because of diarrhea. For years, this led to mandatory loperamide prophylaxis for the first 56 days .
CONTROL changed this approach. On July 1, 2021, the FDA added the option of dose escalation to the neratinib label: starting the drug itself at a low dose and increasing it gradually was found more effective than loperamide prophylaxis.
CONTROL Study — Incidence of Grade 3 Diarrhea
Different strategies to prevent diarrhea when starting neratinib
Discontinuation due to diarrhea: 17% without prophylaxis, 20% with loperamide prophylaxis, and with dose escalation, 3%.
The current label (December 2025) states: if dose escalation is not used, loperamide prophylaxis is given for the first 56 days (weeks 1-2: 4 mg 3 times daily; weeks 3-8: 4 mg 2 times daily; then as needed). If dose escalation is used (week 1: 120 mg; week 2: 160 mg; from week 3: 240 mg), loperamide is given as needed , with no mandatory prophylaxis.
4. Other Targeted Drugs
| Drug | Diarrhea (All Grades / Grade ≥3) | Approach |
|---|---|---|
| Afatinib | 95% / 14% | The highest-risk EGFR TKI; loperamide at the first loose stool |
| Dacomitinib | 87% / 9% | Loperamide at the first loose stool |
| Tucatinib | 81% / 12% (HER2CLIMB) | No routine prophylaxis required; treat if diarrhea develops. Two patients were reported to have died with Grade 4 diarrhea |
| Abemaciclib | 81-90% / 8-20% | Median onset: days 6-8. Start an antidiarrheal “at the first sign of loose stools”; interrupt the drug for Grade 3-4, then resume one dose level lower after recovery to Grade ≤1 |
| Osimertinib | 60% / 3% | As needed |
| Erlotinib, gefitinib | 38-52% / 2-5% | As needed |
The general rule for these drugs is: for Grade 1-2 diarrhea, a 4 mg loading dose, followed by 2 mg after each loose stool or every 4 hours; reassess within 24-48 hours. Grade 3-4 diarrhea is not something to manage at home with loperamide; it requires hospital assessment.
5. If Loperamide Is Insufficient: Octreotide
If chemotherapy-associated diarrhea does not respond to loperamide within 24 hours, treatment is escalated to octreotide:
- Grade 1-2, resistant to loperamide: 100-150 µg subcutaneously 3 times daily
- Grade 3-4: 150 µg 3 times daily; if there is no improvement within 24 hours, increase to 300-500 µg 3 times daily.
- Complicated diarrhea (fever, neutropenia, dehydration, bleeding, signs of sepsis): hospitalization, intravenous fluids and usually intravenous antibiotics
Diarrhea Grading (CTCAE v5.0)
| Grade | Definition | What to Do |
|---|---|---|
| Grade 1 | Increase in daily stool frequency above baseline by fewer than 4 stools | Loperamide + fluids; monitor at home |
| Grade 2 | Above baseline, an increase of 4-6 stools; limits daily activities | Loperamide + fluids; notify the oncologist if there is no response within 24-48 hours |
| Grade 3 | Above baseline, an increase of 7 or more stools; requires hospitalization; limits self-care | Hospital assessment |
| Grade 4 | Life-threatening consequences | Emergency |
Situations in Which Loperamide Must Not Be Used
This is the most important section of the article. Loperamide causes harm when it is used in the wrong patient.
| Situation | Why It Is Not Used |
|---|---|
| Bloody stools (dysentery) | Indicates invasive bacterial infection. Stopping bowel movements prolongs the time microorganisms and toxins remain in the intestine. |
| Diarrhea with fever | Suggests systemic infection; the cause must be investigated first. |
| Suspected E. coli O157:H7 / STEC | Keeping Shiga toxin in the intestine longer increases the risk of hemolytic uremic syndrome , a serious condition that can cause kidney failure. |
| Salmonella, Shigella, Campylobacter | Contraindicated in the label |
| Pseudomembranous colitis / C. difficile | Toxin accumulation in the intestine creates a risk of ileus and toxic megacolon . Before effective treatment has been started and in fulminant disease, it must never be used. |
| Ulcerative colitis flare | Risk of toxic megacolon |
| Abdominal pain without diarrhea | May mask a surgical condition |
| Below age 12 (Turkey) | Contraindicated |
| Abdominal distension, constipation, suspected ileus | Further suppression of peristalsis is dangerous |
Why Are the Rules So Strict for Children? PLoS Medicinepublished a meta-analysis in 2007 pooling 13 studies. It found an adverse-event rate in children taking loperamide of 10% (versus 2% with placebo), and a serious adverse-event rate (ileus, lethargy or death) of 0.9% (versus 0% with placebo). The critical detail: all serious events occurred in children younger than 3. The benefit was modest: diarrhea duration was shortened by 0.8 days , and stool frequency in the first 24 hours fell by 16%. The World Health Organization and UNICEF recommend against antidiarrheal drugs in childhood diarrhea; treatment centers on oral rehydration and zinc .
Immunotherapy-Related Colitis: A Special and Dangerous Exception
Examples include nivolumab, pembrolizumab, atezolizumab and ipilimumab: these immune checkpoint inhibitors cause diarrhea that is fundamentally different from chemotherapy-associated diarrhea. It is driven by immune-mediated inflammation of the intestinal mucosa, and its treatment is corticosteroids, not antidiarrheals.
Examples include nivolumab, pembrolizumab, atezolizumab and ipilimumab: these immune checkpoint inhibitors cause diarrhea that is fundamentally different from chemotherapy-associated diarrhea. It is driven by immune-mediated inflammation of the intestinal mucosa, and its treatment is corticosteroids, not antidiarrheals.
- In this setting, loperamide is acceptable only for Grade 1 diarrhea and only after infection (particularly C. difficile) has been excluded .
- Trying to manage Grade 2 or higher diarrhea with loperamide is harmful: it masks symptoms and delays corticosteroid initiation.
- If endoscopy shows ulceration, antimotility drugs must not be used.
- Toxic megacolon and perforation are real risks in this scenario.
Hydration: The Main Treatment for Diarrhea
The life-threatening problem in diarrhea is fluid and electrolyte loss, rather than diarrhea itself. Loperamide reduces symptoms; it does not replace what has been lost. In a patient receiving chemotherapy, these losses can impair kidney function and lead to treatment delays.
Proper Oral Rehydration (ORS)
The safest option is to obtain ready-made ORS sachets from a pharmacy. The World Health Organization's low-osmolarity formula has the following composition:
| Component | Per Liter | Ion | mmol/L |
|---|---|---|---|
| Sodium chloride | 2.6 g | Sodium | 75 |
| Glucose (anhydrous) | 13.5 g | Chloride | 65 |
| Potassium chloride | 1.5 g | Potassium | 20 |
| Trisodium citrate dihydrate | 2.9 g | Citrate | 10 |
| Total osmolarity | 245 mOsm/L | ||
Correction: The Homemade Recipe. The older text replaced by this article described a homemade solution containing “1 level teaspoon of salt + 8 teaspoons of sugar per 1 liter of water.” The amount of salt in that recipe is approximately twice what it should be and is harmful. The correct recipe recommended by the World Health Organization and UNICEF is:
To 1 liter of clean water (boiled and cooled), add → half a level teaspoon of salt + 6 level teaspoons of sugar.
Why it matters: excess salt draws water into the intestine, increasing diarrhea (osmotic diarrhea), and raises blood sodium, causing restlessness, drowsiness and seizures , and, in severe cases, cerebral edema. Excess sugar has the same osmotic effect. The imbalance is this: overdiluting the mixture is harmless, but making it too salty is not — when uncertain, keep it more dilute. A practical check: the mixture should not taste saltier than tears.
The homemade recipe also contains no potassium or citrate; it therefore does not correct low blood potassium or acid accumulation. Both problems are common in chemotherapy-associated diarrhea. For this reason, the homemade recipe is a temporary solution when ready-made ORS is unavailable.
To 1 liter of clean water (boiled and cooled), add → half a level teaspoon of salt + 6 level teaspoons of sugar.
Why it matters: excess salt draws water into the intestine, increasing diarrhea (osmotic diarrhea), and raises blood sodium, causing restlessness, drowsiness and seizures , and, in severe cases, cerebral edema. Excess sugar has the same osmotic effect. The imbalance is this: overdiluting the mixture is harmless, but making it too salty is not — when uncertain, keep it more dilute. A practical check: the mixture should not taste saltier than tears.
The homemade recipe also contains no potassium or citrate; it therefore does not correct low blood potassium or acid accumulation. Both problems are common in chemotherapy-associated diarrhea. For this reason, the homemade recipe is a temporary solution when ready-made ORS is unavailable.
- Take frequent, small sips; drinking a large amount at once can trigger vomiting.
- Cola, fruit juices and sports drinks do not replace ORS — their sugar content is high and their electrolyte composition is unsuitable, and they may worsen diarrhea.
- Temporarily avoid fatty, spicy and high-fiber foods, as well as dairy products ; transient lactose intolerance is common during diarrhea.
- Mild, binding foods such as bananas, rice, applesauce and toast may be introduced if tolerated.
- In patients with kidney failure, heart failure or a tendency to sodium imbalance, the fluid plan should be determined by a physician.
Side Effects and Boxed Warning
| Frequency | Side Effect |
|---|---|
| Common | Constipation (2-5%), dizziness, nausea, abdominal cramps, gas |
| Uncommon | Rash, dry mouth, drowsiness, difficulty urinating |
| Serious (Overdose/Abuse) | QT prolongation, ventricular tachycardia, torsades de pointes, cardiac arrest, respiratory depression, paralytic ileus, toxic megacolon |
| Very rare | Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema |
Prescription loperamide products in the US carry a boxed warning:
“WARNING: TORSADES DE POINTES AND SUDDEN DEATH — Cases of torsades de pointes, cardiac arrest and death have been reported with doses higher than recommended. Contraindicated in children younger than 2 years. Because of the risk of serious cardiac adverse reactions, avoid doses higher than recommended in adults and children older than 2 years.”
This warning was added to the label in October 2016 and remains in effect. Nonprescription products do not use the boxed-warning format — this does not mean the risk is lower; it only means that the label format differs.
“WARNING: TORSADES DE POINTES AND SUDDEN DEATH — Cases of torsades de pointes, cardiac arrest and death have been reported with doses higher than recommended. Contraindicated in children younger than 2 years. Because of the risk of serious cardiac adverse reactions, avoid doses higher than recommended in adults and children older than 2 years.”
This warning was added to the label in October 2016 and remains in effect. Nonprescription products do not use the boxed-warning format — this does not mean the risk is lower; it only means that the label format differs.
How Does Cardiotoxicity Develop?
At very high doses, loperamide blocks two separate ion channels in heart muscle:
- hERG potassium channel → repolarization is delayed → QT prolongation → torsades de pointes
- Nav1.5 sodium channel → QRS widening, Brugada-like patterns and ventricular tachycardia
This dual blockade places loperamide in the same risk category as its structural relatives methadone and haloperidol.
Abuse: “Poor Man's Methadone”
At normal doses, loperamide does not enter the brain. However, at 50-100 times higher doses (100-400 mg daily, or 50-200 tablets), the P-glycoprotein pump at the blood-brain barrier becomes saturated and the drug reaches the central nervous system, producing opioid effects. Its use in this way to relieve opioid withdrawal has been called “poor man's methadone.”
The outcome is often fatal. The FDA's safety communication dated June 7, 2016 reported, for the period 1976-2015, 48 serious cardiac events, 31 hospitalizations and 10 deaths . More than half of the cases occurred after 2010. On January 30, 2018, the FDA requested packaging changes, and on September 20, 2019, it approved new packaging: blister packs containing no more than 48 mg of loperamide per pack.
These Regulations Worked. Injury Epidemiology published a study in 2023 examining reports to US poison centers from 2010-2022. The study reviewed 12987 loperamide cases and found that case numbers peaked in 2017 at 1509 , then fell in 2022 to 922(a 38.9% decrease). The abuse rate was 0.06 per 100000 in 2016 and fell in 2022 to 0.01. Across the entire series, serious medical outcomes occurred in 13.4%, with 59 deaths (0.5%), and 60% of deaths were associated with abuse. Among abuse cases, the risk of a serious outcome was 7.9 times higher.
An Important Detail in Poisoning: Naloxonereverses loperamide-induced respiratory and central nervous system depression, but has no effect on cardiotoxicity. Fatal arrhythmias can occur even without any opioid symptoms. Therefore, suspected cases require ECG monitoring and prolonged observation . Sodium bicarbonate is used for QRS widening, magnesium sulfate for torsades, and isoproterenol or temporary cardiac pacing when necessary.
Drug Interactions
Loperamide is a P-glycoprotein substrate and is metabolized in the liver through CYP3A4 and CYP2C8 . Drugs that inhibit these two pathways increase loperamide levels in the blood and brain.
| Group | Examples | Effect | What to Do |
|---|---|---|---|
| P-gp inhibitors | Quinidine, verapamil, ritonavir, clarithromycin, cyclosporine, itraconazole | Increased brain penetration and blood levels; greater central nervous system and cardiac risk | If used together, keep the dose lowand the duration short |
| CYP3A4 / CYP2C8 inhibitors | Ketoconazole, itraconazole, gemfibrozil, ritonavir, clarithromycin, grapefruit juice | Increased blood levels; possibility of QT prolongation | Immediate assessment for cardiac symptoms |
| CYP inducers | Rifampicin, carbamazepine, phenytoin, St. John's wort | Loperamide levels decrease; it may become ineffective | Check for these drugs if there is no response |
| QT-prolonging drugs | Sotalol, amiodarone, haloperidol, citalopram, ondansetron, some antibiotics | Risks are additive | Avoid concomitant use if possible; ECG monitoring if necessary |
| CNS depressants | Benzodiazepines, opioids, first-generation antihistamines, alcohol | Risk of respiratory depression with high loperamide doses | Avoid overdose |
| Desmopressin | Loperamide may increase absorption of oral desmopressin threefold . | Caution with concomitant use |
A Practical Warning for Patients With Cancer: Most patients with cancer already take antiemetics (ondansetron), antifungals (fluconazole, itraconazole), antibiotics (clarithromycin, levofloxacin) or antidepressants. Many of these either prolong QT or inhibit loperamide metabolism. A new drug taken when diarrhea begins must be assessed alongside the existing medication list — this is not a calculation patients can make on their own.
Special Populations
| Group | Approach |
|---|---|
| Hepatic Impairment | Blood levels may increase substantially because first-pass metabolism is impaired. Use cautiously, at a low dose and for a short period; monitor for central nervous system symptoms. |
| Renal Impairment | Elimination is largely through feces; dose adjustment is generally unnecessary. However, hydration is important because diarrhea itself can impair kidney function. |
| Children | In Turkey, contraindicated below age 12. Oral rehydration and zinc are central to treating childhood diarrhea. |
| Older Adults | No dose adjustment is required, but dehydration, electrolyte disturbances, polypharmacy and QT risk require close monitoring . |
| Pregnancy | See the note below. |
| Breastfeeding | Small amounts pass into breast milk; the label states that use while breastfeeding is not recommended . |
| Ileostomy | May be used on medical advice to reduce stool volume; dose requirements may differ in this group. |
About “Category C” in Pregnancy. The FDA changed its A/B/C/D/X letter-category system on June 30, 2015, under the Pregnancy and Lactation Labeling Rule that took effect on that date: the system was abolished. However, because loperamide labels were never converted to the new format, current prescribing information still states “Pregnancy Category C.” Human data are limited and conflicting: a prospective study in 2000 found no increase in major malformations but suggested lower birth weight; Swedish birth-registry data from a 2008 study reported an approximately 1.5-fold increase in major malformation risk and a higher frequency of hypospadias. The UK teratology information service considers the results of three studies involving more than 800 exposed infants conflicting and states that no increased risk of miscarriage, low birth weight or preterm birth was found. Conclusion: use during pregnancy only if necessary and on a physician's decision.
Pharmacokinetics
| Parameter | Value | Clinical Significance |
|---|---|---|
| Oral bioavailability | Below 1% (approximately 0.3% in the literature) | Local intestinal action; almost no systemic effect |
| Plasma level | < 2 ng/mL after 2 mg | Too low to measure |
| Time to peak (Tmax) | ~5 hours (capsule), 2.5 hours (liquid) | Action begins quickly, but peak levels occur later |
| Protein binding | ~95% (albumin) | |
| Half-life | 10.8 hours (9.1-14.4) | In poisoning, toxicity is prolonged; much longer than naloxone |
| Metabolism | N-demethylation; mainly CYP3A4 and CYP2C8 | Source of interactions |
| Main metabolite | N-desmethyl loperamide | |
| Transporter | P-glycoprotein substrate | Prevents brain penetration; the pump becomes saturated at high doses |
| Elimination | Mainly through feces (via bile); ~1% in urine | No dose adjustment required in renal impairment |
Effectiveness: How Much Does Loperamide Really Help?
Loperamide provides a real benefit, but it should not be exaggerated. In acute infectious diarrhea, its effect is not to speed recovery, but to make symptoms tolerable.
- In children (2007 meta-analysis): diarrhea duration was reduced by 0.8 days , and stool frequency in the first 24 hours showed a 16% reduction — balanced against a risk of serious adverse events. This balance explains why the drug is not recommended in children.
- With Antibiotics for Travelers' Diarrhea (2008 meta-analysis, 1435 patients): the likelihood of clinical recovery at 24 hours was 2.58 times higher, and at 48 hours, 2.15 times higher . However, at 72 hours the difference was no longer significant (OR 1.40; not significant) — loperamide brings recovery forward but does not change the outcome. Campylobacterwas common in regions where a study found no benefit.
In Oncology, the Equation Is Different. In chemotherapy-associated diarrhea, the goal is not merely comfort, but the ability to continue treatment. Uncontrolled diarrhea leads to dose reductions, cycle delays and complete treatment discontinuation — in the neratinib example, among patients without prophylaxis, 17% stopped the drug for this reason. In this context, loperamide is not simply a comfort measure, but supportive therapy that helps sustain treatment.
When Should You Seek Medical Advice?
If any of the following occurs, do not take loperamide or stop it and seek medical advice:
- Fever (38°C or higher) — in a patient receiving chemotherapy, this alone is an emergency
- Blood in the stool or black, tarry stools
- Severe abdominal pain, abdominal distension, inability to pass gas or stool
- Diarrhea not improving within 48 hours
- Dry mouth, markedly reduced urine output, dizziness on standing, palpitations — signs of dehydration .
- Muscle cramps, profound weakness — may indicate low potassium .
- Palpitations, fainting or near-fainting, chest pain — require urgent assessment for an arrhythmia .
- If you are receiving chemotherapy or immunotherapy and diarrhea has just begun: call your oncology team without delay
Frequently Asked Questions
- Can Lopermid Be Bought Without a Prescription?
- In Turkey, it requires a standard white prescription. The fact that pharmacies may supply it without a prescription in practice does not change its legal status. More importantly, patients cannot distinguish most situations in which it must not be used (invasive bacterial diarrhea, C. difficileand immunotherapy-related colitis).
- How Many Tablets Can I Take?
- According to the Turkish Summary of Product Characteristics, the maximum per day is 6 tablets (12 mg). The intensive regimen for irinotecan delayed diarrhea deliberately exceeds this limit, but is used only on an oncologist's instructions and for no more than 48 hours.
- How Quickly Does It Work?
- The initial effect usually begins within 1-2 hours. Clear improvement in uncomplicated acute diarrhea is expected within 24-48 hours; seek medical advice if it does not occur.
- Can I Take It Immediately if I Develop Diarrhea During Chemotherapy?
- Yes, if your oncologist has already given you a plan — in chemotherapy-associated diarrhea, starting early is important. However, if fever, bloody stools or neutropenia are present, do not take it and notify your team immediately. If you are receiving immunotherapy, the cause of diarrhea may differ; talk to your team first.
- Is It Addictive?
- Not at normal doses; the drug does not enter the brain. However, at very high doses (100 mg or more per day), opioid effects occur, and this pattern of use carries a risk of both addiction and fatal arrhythmias .
- Can I Use It for Antibiotic-Associated Diarrhea?
- Caution is required. Some diarrhea after antibiotics is caused by C. difficile infection, and loperamide can then cause toxin accumulation in the intestine. If fever, bloody stools or severe abdominal pain are present, it must never be used , and testing is needed.
- It Caused Constipation. What Should I Do?
- Stop the drug and maintain fluid intake. Constipation is loperamide's most common side effect and usually resolves after discontinuation. If abdominal distension, vomiting and inability to pass gas also occur, this may be paralytic ileus and requires urgent assessment.
- Is It the Same as Imodium?
- The active ingredient is the same (loperamide). However, Imodium is not authorized in Turkey; the only authorized product in the country is Lopermid.
- Can I Give It to My Child?
- Not below age 12 — it is contraindicated in Turkey. Proper treatment of childhood diarrhea is oral rehydration and zinc. Antidiarrheal drugs have been associated with serious adverse events in children younger than 3.
Transparency Note. Points in this article that we could not verify or that may change: (1) Lopermid's SGK reimbursement and listing under reimbursement code A04735 were confirmed in two independent Turkish drug databases; however, the text of SUT Annex-4/A on whether a medical report is required could not be verified directly. The older text's statement that it is reimbursed without a report was therefore not confirmed. (2) For the FDA's 1988 nonprescription approval, the exact date could not be confirmed; secondary sources give only the year and March 1988. (3) For Shiga toxin-producing E. coli infection, no numerical estimate was providedfor how much antimotility drugs increase hemolytic uremic syndrome risk; although the mechanism and guideline prohibition are known, a reliable rate could not be verified. (4) Loperamide's role in immunotherapy-related colitis was compiled from ONS, the MD Anderson algorithm and a 2025 review — the full ASCO and NCCN guidelines could not be accessed. (5) The product “Diaraphil” mentioned in the older text could not be found in any Turkish or international drug database. Drug prices change frequently in Turkey; confirm the price in the pharmacy system before purchase.
This article is for information and does not replace personal medical advice. In patients receiving cancer treatment, diarrhea may be both a treatment side effect and a symptom of a separate disease; assessment should be undertaken by the oncology team.
References
- LOPERMİD 2 mg tablet Kısa Ürün Bilgisi, Saba İlaç; revised 26.03.2025.
- T.C. Sağlık Bakanlığı İlaç Fiyat Listesi, August 31, 2026.
- Beşeri Tıbbi Ürünlerin Sınıflandırılmasına Dair Yönetmelik, Resmî Gazete 17.02.2005, No. 25730.
- IMODIUM (loperamide HCl) US Prescribing Information, label with boxed warning; NDA 017694/S-052, October 2016; current generic label revised 11/2025.
- FDA Drug Safety Communication: serious heart problems with high doses of loperamide, June 7, 2016; request for packaging restrictions, January 30, 2018; approval of new packaging, September 20, 2019.
- CAMPTOSAR (irinotecan) US Prescribing Information, Pfizer; revised 6/2024.
- NERLYNX (neratinib) US Prescribing Information; dose-escalation approval July 1, 2021; current label 12/2025.
- Barcenas CH, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol 2020;31:1223-30; final results The Breast 2022.
- Patel A, Rine NI, et al. Loperamide cases reported to United States poison centers, 2010-2022. Injury Epidemiology 2023;10.
- Li ST, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. PLoS Med 2007;4(3):e98.
- Riddle MS, Arnold S, Tribble DR. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: systematic review and meta-analysis. Clin Infect Dis 2008;47:1007-14.
- Shane AL, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clin Infect Dis 2017;65:e45-e80.
- American College of Gastroenterology Clinical Guideline: prevention, diagnosis and treatment of Clostridioides difficile infections, 2021.
- World Health Organization / UNICEF Joint Statement: Clinical Management of Acute Diarrhoea; low-osmolarity ORS formulation.
- Källén B, Nilsson E, Otterblad Olausson P. Maternal use of loperamide in early pregnancy and delivery outcome. Acta Paediatr 2008;97:541-5; Einarson A, et al. Am J Gastroenterol 2000;95:2205-6; UK Teratology Information Service, loperamide monograph.
- BC Cancer, Guidelines for the Management of Chemotherapy-Induced Diarrhea.
- Common Terminology Criteria for Adverse Events (CTCAE) v5.0, diarrhea grading.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.